tiprankstipranks
Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
India Market
MANKIND
Mankind Pharma Ltd.
RESEARCH TOOLSreports
Want to see IN:MANKIND full AI Analyst Report?

Mankind Pharma Ltd. (MANKIND) Stock Forecast & Price Target

14 Followers
See the Price Targets and Ratings of:

MANKIND Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Mankind
Pharma Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,830.00
▲(28.49% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Mankind Pharma Ltd. in the last 3 months. The average price target is ₹2,830.00 with a high forecast of ₹3,000.00 and a low forecast of ₹2,640.00. The average price target represents a 28.49% change from the last price of ₹2,202.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2000":"₹2,000","3001":"₹3,001","2250.25":"₹2,250.3","2500.5":"₹2,500.5","2750.75":"₹2,750.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2830,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.83K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2640,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.64K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2000,2250.25,2500.5,2750.75,3001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2304.5076923076927,2362.4653846153847,2420.423076923077,2478.380769230769,2536.3384615384616,2594.296153846154,2652.253846153846,2710.2115384615386,2768.169230769231,2826.126923076923,2884.0846153846155,2942.0423076923075,{"y":3000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2291.4307692307693,2336.3115384615385,2381.1923076923076,2426.073076923077,2470.9538461538464,2515.8346153846155,2560.7153846153847,2605.596153846154,2650.476923076923,2695.3576923076926,2740.2384615384617,2785.119230769231,{"y":2830,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2246.55,2276.8153846153846,2307.0807692307694,2337.346153846154,2367.6115384615387,2397.876923076923,2428.142307692308,2458.4076923076923,2488.673076923077,2518.9384615384615,2549.2038461538464,2579.4692307692308,2609.7346153846156,{"y":2640,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2462.73,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2413.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2287.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2244.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2001.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2246.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹3,000Average Price Target₹2,830Lowest Price Target₹2,640
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on IN:MANKIND
Bansi Desai
J.P. Morgan
J.P. Morgan
₹2,850
Buy
29.40%
Upside
Reiterated
05/22/26
J.P. Morgan Keeps Their Buy Rating on Mankind Pharma Ltd. (MANKIND)
Jefferies Analyst forecast on IN:MANKIND
Alok Dalal
Jefferies
Jefferies
₹3,000
Buy
36.21%
Upside
Reiterated
05/20/26
Mankind Pharma Ltd. (MANKIND) Receives a Buy from Jefferies
Motilal Oswal Analyst forecast on IN:MANKIND
Tushar Manudhane
Motilal Oswal
Motilal Oswal
₹2,640
Buy
19.86%
Upside
Reiterated
04/29/26
We value Mankind at 35x 12M forward earnings to arrive at a TP of INR2,640. Reiterate BUY.
Geojit Research Analyst forecast on IN:MANKIND
Unknown Analyst
Geojit Research
Not Ranked
Geojit Research
₹2,691→₹2,600
Buy
18.04%
Upside
Upgraded
11/26/25
Geojit Research upgrades Mankind Pharma Ltd. (MANKIND) to a Buy
Kotak Mahindra Analyst forecast on IN:MANKIND
Alankar Garude
Kotak Mahindra
Kotak Mahindra
₹2,800
Buy
27.13%
Upside
Reiterated
09/29/25
Kotak Mahindra Sticks to Its Buy Rating for Mankind Pharma Ltd. (MANKIND)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on IN:MANKIND
Bansi Desai
J.P. Morgan
J.P. Morgan
₹2,850
Buy
29.40%
Upside
Reiterated
05/22/26
J.P. Morgan Keeps Their Buy Rating on Mankind Pharma Ltd. (MANKIND)
Jefferies Analyst forecast on IN:MANKIND
Alok Dalal
Jefferies
Jefferies
₹3,000
Buy
36.21%
Upside
Reiterated
05/20/26
Mankind Pharma Ltd. (MANKIND) Receives a Buy from Jefferies
Motilal Oswal Analyst forecast on IN:MANKIND
Tushar Manudhane
Motilal Oswal
Motilal Oswal
₹2,640
Buy
19.86%
Upside
Reiterated
04/29/26
We value Mankind at 35x 12M forward earnings to arrive at a TP of INR2,640. Reiterate BUY.
Geojit Research Analyst forecast on IN:MANKIND
Unknown Analyst
Geojit Research
Not Ranked
Geojit Research
₹2,691→₹2,600
Buy
18.04%
Upside
Upgraded
11/26/25
Geojit Research upgrades Mankind Pharma Ltd. (MANKIND) to a Buy
Kotak Mahindra Analyst forecast on IN:MANKIND
Alankar Garude
Kotak Mahindra
Kotak Mahindra
₹2,800
Buy
27.13%
Upside
Reiterated
09/29/25
Kotak Mahindra Sticks to Its Buy Rating for Mankind Pharma Ltd. (MANKIND)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mankind Pharma Ltd.

3 Months
Bansi DesaiJ.P. Morgan
Success Rate
3/5 ratings generated profit
60%
Average Return
-0.94%
Copying Bansi Desai's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -0.94% per trade.
1 Year
Bansi DesaiJ.P. Morgan
Success Rate
2/5 ratings generated profit
40%
Average Return
+0.88%
Copying Bansi Desai's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +0.88% per trade.
2 Years
Bansi DesaiJ.P. Morgan
Success Rate
2/5 ratings generated profit
40%
Average Return
+3.62%
Copying Bansi Desai's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +3.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MANKIND Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
2
1
1
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
1
1
2
3
In the current month, MANKIND has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MANKIND average Analyst price target in the past 3 months is 2,830.00.
Each month's total comprises the sum of three months' worth of ratings.

MANKIND Financial Forecast

MANKIND Earnings Forecast

The previous quarter’s earnings for MANKIND were ₹14.00.
The previous quarter’s earnings for MANKIND were ₹14.00.

MANKIND Sales Forecast

The previous quarter’s earnings for MANKIND were ₹34.43B.
The previous quarter’s earnings for MANKIND were ₹34.43B.

MANKIND Stock Forecast FAQ

What is IN:MANKIND’s average 12-month price target, according to analysts?
Based on analyst ratings, Mankind Pharma Ltd.’s 12-month average price target is 2,830.00.
    What is IN:MANKIND’s upside potential, based on the analysts’ average price target?
    Mankind Pharma Ltd. has 28.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Mankind Pharma Ltd. a Buy, Sell or Hold?
          Mankind Pharma Ltd. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mankind Pharma Ltd.’s share price target?
            The average share price target for Mankind Pharma Ltd. is 2,830.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹3,000.00 ,and the lowest forecast is ₹2,640.00. The average share price target represents 28.49% Increase from the current price of ₹2,202.55.
              What do analysts say about Mankind Pharma Ltd.?
              Mankind Pharma Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Mankind Pharma Ltd.?
                To buy shares of IN:MANKIND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.